Payers May Balk at Newly Approved ALS Drug’s $158K Price

The FDA on Sept. 29 approved Relyvrio (sodium phenylbutyrate/taurusodiol), making it only the third medication to treat patients with amyotrophic lateral sclerosis (ALS). While ALS advocates and some clinicians applauded the agency’s decision, other providers have questioned the drug’s effectiveness, and some experts believe the drug is not cost-effective with its approximately $158,000 annual wholesale acquisition cost (WAC).

For instance, the nonprofit Institute for Clinical and Economic Review (ICER) found that Relyvrio, which was formerly known as AMX0035, would be cost-effective if it was priced at between $9,100 and $30,600 per year. And Bruce Booth, a former scientist who’s now a partner at the Atlas Venture biotechnology venture capital firm, wrote on Twitter that the $158,000 price for Relyvrio was “even more egregious than I thought!”

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

fda
September 8

FDA Committee Backs ALS Drug as ICER Questions Projected Cost

READ MORE
cms-website
April 14

Payers Applaud as CMS Stands Ground on Aduhelm Coverage

READ MORE
holding-an-elderly's-hand
January 13

Medicare Plans to Cover Aduhelm but With Certain Restrictions

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today